Q-omics provides the consensus-scored PRR13P7 profile across patient tissues and cancer cell-line models. PRR13P7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, PRR13P7 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, PRR13P7 RNA expression shows 4,536 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, and STAD as cancer lineages where PRR13P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR13P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR13P7 survival associations across molecular data types. PRR13P7 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR13P7 RNA expression–survival associations across cancer types. High PRR13P7 expression shows unfavorable associations in THYM, ACC, KICH, LUSC, THCA and SKCM. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for PRR13P7 RNA expression.
This table summarizes PRR13P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRR13P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR13P7 shows lower tumor expression in STAD, ESCA and KIRC. The STAD box plot shows higher PRR13P7 RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p < 0.001).
This table shows molecular features associated with PRR13P7 in patient tissues and cancer cell lines. In patient samples, PRR13P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
